Cannabidiol as a potential treatment for psychosis.

Author(s): Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP

Tergooi Hospital, Department of Psychiatry, Blaricum, The Netherlands

Subject: Schizophrenia View the study


Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties. This review concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the antipsychotic properties of CBD.

Source: European Neuropsychopharmacology (Price: $36)
Share Tweet

More medical studies related to Schizophrenia:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

узнать больше